Chemoprevention with mitochondria-targeted honokiol in mouse models of lung cancer: adenocarcinoma and squamous cell carcinoma
Ended Awarded Last action
- Contract number
- 75N91022F00004
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,201,554
Award facts
- Opportunity
-
- TORFP2022E07 Solicitation number
- Contract value 100% obligated
- $1,201,554.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,201,554 |
About this award
The National Cancer Institute issued a delivery order to the University of Oklahoma's Health Sciences Center on September 15, 2022, with a ceiling value of $1,201,554 under the PREVENT Preclinical Drug Development Program IDIQ for chemoprevention research using mitochondria-targeted honokiol in mouse models of lung cancer (adenocarcinoma and squamous cell carcinoma).
Place of performance is Oklahoma City, OK. The order has a firm fixed-price structure and an ultimate completion date of March 14, 2026. Under the PREVENT vehicle, the Health Sciences Center delivers preclinical drug development supporting cancer prevention drug development through multiple delivery orders issued by the National Cancer Institute.
Service Contract Inventory reporting shows actual government-invoiced labor for FY2023–FY2025. In FY2023, the order generated $300 thousand in invoiced labor across 0.9 FTEs and 1,831 contractor hours at a derived rate of $164.07 per hour. FY2024 invoicing reached $401 thousand across 1.1 FTEs and 2,332 contractor hours at $171.77 per hour. FY2025 activity invoiced $401 thousand across 1.8 FTEs and 3,705 contractor hours at a blended rate of $108.10 per hour, with one subcontractor performing 92 percent of contractor hours. The derived hourly rate declined across the three-year period.
Quick answers
Who was awarded contract 75N91022F00004?
75N91022F00004 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 15, 2022.
How much is contract 75N91022F00004 worth?
The government has obligated $1,201,554 on 75N91022F00004.
Is contract 75N91022F00004 an order under another contract?
Yes. 75N91022F00004 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91022F00004 competed?
The extent of competition for 75N91022F00004 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award